HealthMore in Health→
Ipsen Pulls Cancer Drug Tazverik Over Secondary Cancer Risk
Key Takeaways
- Data monitoring committee found secondary blood cancers in confirmatory trial patients
- Tazverik was approved under accelerated pathway for rare epithelioid sarcoma
- Withdrawal raises questions about long-term safety of EZH2 inhibitor drug class
DE
DT Editorial Team··4 min read·via endpoints.news
